Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SF1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SF1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SF1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SF1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SF1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SF1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SF1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SF1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SF1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0043618113 | Thyroid | PTC | regulation of transcription from RNA polymerase II promoter in response to stress | 31/5968 | 47/18723 | 1.64e-06 | 2.30e-05 | 31 |
GO:000862523 | Thyroid | PTC | extrinsic apoptotic signaling pathway via death domain receptors | 47/5968 | 82/18723 | 1.70e-06 | 2.38e-05 | 47 |
GO:0043281113 | Thyroid | PTC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 99/5968 | 209/18723 | 1.93e-06 | 2.64e-05 | 99 |
GO:0034605113 | Thyroid | PTC | cellular response to heat | 41/5968 | 69/18723 | 2.17e-06 | 2.91e-05 | 41 |
GO:0010952113 | Thyroid | PTC | positive regulation of peptidase activity | 94/5968 | 197/18723 | 2.34e-06 | 3.11e-05 | 94 |
GO:0008630112 | Thyroid | PTC | intrinsic apoptotic signaling pathway in response to DNA damage | 54/5968 | 99/18723 | 2.46e-06 | 3.22e-05 | 54 |
GO:000110119 | Thyroid | PTC | response to acid chemical | 69/5968 | 135/18723 | 2.55e-06 | 3.34e-05 | 69 |
GO:00314406 | Thyroid | PTC | regulation of mRNA 3'-end processing | 21/5968 | 28/18723 | 3.46e-06 | 4.46e-05 | 21 |
GO:2000116113 | Thyroid | PTC | regulation of cysteine-type endopeptidase activity | 108/5968 | 235/18723 | 3.99e-06 | 4.99e-05 | 108 |
GO:0009408112 | Thyroid | PTC | response to heat | 58/5968 | 110/18723 | 4.48e-06 | 5.52e-05 | 58 |
GO:00436315 | Thyroid | PTC | RNA polyadenylation | 29/5968 | 45/18723 | 7.13e-06 | 8.38e-05 | 29 |
GO:0052547113 | Thyroid | PTC | regulation of peptidase activity | 191/5968 | 461/18723 | 7.82e-06 | 9.02e-05 | 191 |
GO:0002064112 | Thyroid | PTC | epithelial cell development | 101/5968 | 220/18723 | 8.53e-06 | 9.74e-05 | 101 |
GO:007148018 | Thyroid | PTC | cellular response to gamma radiation | 22/5968 | 31/18723 | 9.07e-06 | 1.03e-04 | 22 |
GO:004668517 | Thyroid | PTC | response to arsenic-containing substance | 23/5968 | 33/18723 | 9.16e-06 | 1.04e-04 | 23 |
GO:200123820 | Thyroid | PTC | positive regulation of extrinsic apoptotic signaling pathway | 30/5968 | 48/18723 | 1.23e-05 | 1.34e-04 | 30 |
GO:00062828 | Thyroid | PTC | regulation of DNA repair | 65/5968 | 130/18723 | 1.25e-05 | 1.36e-04 | 65 |
GO:007124318 | Thyroid | PTC | cellular response to arsenic-containing substance | 16/5968 | 20/18723 | 1.31e-05 | 1.42e-04 | 16 |
GO:00063785 | Thyroid | PTC | mRNA polyadenylation | 28/5968 | 44/18723 | 1.46e-05 | 1.56e-04 | 28 |
GO:1901654113 | Thyroid | PTC | response to ketone | 90/5968 | 194/18723 | 1.56e-05 | 1.65e-04 | 90 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SF1 | SNV | Missense_Mutation | novel | c.1782G>A | p.Met594Ile | p.M594I | Q15637 | protein_coding | tolerated_low_confidence(0.12) | benign(0.003) | TCGA-AC-A3OD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | | c.1080N>G | p.Asp360Glu | p.D360E | Q15637 | protein_coding | tolerated(0.21) | benign(0.014) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | | c.1721N>C | p.Gln574Pro | p.Q574P | Q15637 | protein_coding | deleterious_low_confidence(0.01) | benign(0.293) | TCGA-E2-A154-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SF1 | SNV | Missense_Mutation | | c.1138N>T | p.Arg380Trp | p.R380W | Q15637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-WT-AB44-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SF1 | SNV | Missense_Mutation | novel | c.877N>C | p.Glu293Gln | p.E293Q | Q15637 | protein_coding | tolerated(0.11) | probably_damaging(0.997) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | | c.1138C>T | p.Arg380Trp | p.R380W | Q15637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | rs777252081 | c.1297C>T | p.Arg433Trp | p.R433W | Q15637 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | | c.1138C>T | p.Arg380Trp | p.R380W | Q15637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SF1 | SNV | Missense_Mutation | | c.1138N>T | p.Arg380Trp | p.R380W | Q15637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SF1 | SNV | Missense_Mutation | novel | c.806N>C | p.Gln269Pro | p.Q269P | Q15637 | protein_coding | tolerated(0.22) | probably_damaging(0.992) | TCGA-VS-A9UT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |